Message from LeadershipThe 2016 fiscal year advanced GHIT’s pipeline by leaps and bounds. The year was also marked by extraordinary commitments to global health, reminding us that global will is stronger than ever. The Government of Japan pledged $1.1 billion at the G7 Ise-Shima Summit to key global health mechanisms, including $130 million to the GHIT Fund and United Nations Development Programme (UNDP). This pledge serves as a bold demonstration of Japan’s unwavering support for research and development (R&D) for neglected diseases around the world. This commitment builds on a legacy of global health landmarks at previous G7/G8 summits held in Japan.
GHIT also welcomed ten new funding partnerships with major global pharmaceutical and biotechnology companies—collaborations that expand our investment capacity significantly. Additionally, the sixth Tokyo International Conference on African Development (TICAD) took place in Africa for the first time, underscoring Japan’s faith in Africa’s future and emphasizing the inextricable links between health and economic vitality.
The global context for these commitments is marked by stark reminders of the urgency of global health R&D, in the wake of the Ebola and Zika epidemics. The lack of tools and delivery challenges experienced during these epidemics remind us of the scientific and access frontiers we have yet to cross. Indeed, access remains a paramount priority for GHIT. Our focus on ensuring effective, affordable delivery of the innovations that will soon emerge from our pipeline has only grown since our establishment.
Upon the occasion of GHIT’s fifth anniversary in 2017, our motivation to accelerate global health R&D is stronger than ever. We extend our deepest gratitude to the development partners, funders, and sponsors whose creativity, courage, and passion fuel our own.
Kiyoshi Kurokawa, MD
BT Slingsby, MD, PhD, MPH
Chief Executive Officer